INARI MEDICAL INC (NARI) Stock Price, Quote, News and Overview
NASDAQ:NARI - Nasdaq - US45332Y1091 - Common Stock - Currency: USD
NARI Quote, Performance and Key Statistics
79.97
+0.04 (+0.05%)
The current stock price of NARI is 79.97 USD. In the past month the price increased by 0.53%. In the past year, price increased by 40.08%.
NARI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About NARI
Company Profile
Inari Medical, Inc. operates as a medical device company. The company is headquartered in Irvine, California and currently employs 1,300 full-time employees. The company went IPO on 2020-05-22. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. The company also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
Company Info
INARI MEDICAL INC
6001 Oak Canyon, Suite 100
Irvine CALIFORNIA 92618 US
CEO: William Hoffman
Employees: 1300
Company Website: https://www.inarimedical.com
Investor Relations: https://ir.inarimedical.com/
Phone: 19499234747
INARI MEDICAL INC / NARI FAQ
What is the stock price of INARI MEDICAL INC today?
The current stock price of NARI is 79.97 USD. The price increased by 0.05% in the last trading session.
What is the ticker symbol for INARI MEDICAL INC stock?
The exchange symbol of INARI MEDICAL INC is NARI and it is listed on the Nasdaq exchange.
On which exchange is NARI stock listed?
NARI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INARI MEDICAL INC stock?
22 analysts have analysed NARI and the average price target is 76.99 USD. This implies a price decrease of -3.73% is expected in the next year compared to the current price of 79.97. Check the INARI MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INARI MEDICAL INC worth?
INARI MEDICAL INC (NARI) has a market capitalization of 4.68B USD. This makes NARI a Mid Cap stock.
How many employees does INARI MEDICAL INC have?
INARI MEDICAL INC (NARI) currently has 1300 employees.
What are the support and resistance levels for INARI MEDICAL INC (NARI) stock?
INARI MEDICAL INC (NARI) has a support level at 79.89 and a resistance level at 79.98. Check the full technical report for a detailed analysis of NARI support and resistance levels.
Is INARI MEDICAL INC (NARI) expected to grow?
The Revenue of INARI MEDICAL INC (NARI) is expected to grow by 22.24% in the next year. Check the estimates tab for more information on the NARI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INARI MEDICAL INC (NARI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NARI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NARI, evaluating the profitability, health, valuation and growth aspects
- INARI MEDICAL INC (NARI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INARI MEDICAL INC (NARI) Sales and EPS estimates to see what analysts future expectations are.
- INARI MEDICAL INC (NARI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INARI MEDICAL INC (NARI) Insider and Institutional Ownership to learn about the owners and their transactions.
- INARI MEDICAL INC (NARI) Stock Chart to make your own analysis
- INARI MEDICAL INC (NARI) Latest news and press-releases to stay up to date.
Does INARI MEDICAL INC (NARI) stock pay dividends?
NARI does not pay a dividend.
When does INARI MEDICAL INC (NARI) report earnings?
INARI MEDICAL INC (NARI) will report earnings on 2025-03-04, after the market close.
What is the Price/Earnings (PE) ratio of INARI MEDICAL INC (NARI)?
INARI MEDICAL INC (NARI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.77).
What is the Short Interest ratio of INARI MEDICAL INC (NARI) stock?
The outstanding short interest for INARI MEDICAL INC (NARI) is 4.66% of its float. Check the ownership tab for more information on the NARI short interest.
NARI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NARI. When comparing the yearly performance of all stocks, NARI is one of the better performing stocks in the market, outperforming 94.36% of all stocks.
NARI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NARI. While NARI seems to be doing ok healthwise, there are quite some concerns on its profitability.
NARI Financial Highlights
Over the last trailing twelve months NARI reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS decreased by -1183.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.27% | ||
| ROE | -18.07% | ||
| Debt/Equity | 0 |
NARI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to NARI. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of -2492.94% and a revenue growth 22.24% for NARI